Fatality due to acute alpha-methyltryptamine intoxication.
Fatality due to acute alpha-methyltryptamine intoxication.
复制标题
因急性α-甲基色胺中毒而死亡。
DOI：
--
复制
发表时间：
2005
影响因子：
2.5
通讯作者：
W. Hearn
中科院分区：
文献类型：
--
作者：
D. Boland;W. Andollo;G. Hime;W. Hearn
2003年2月，迈阿密戴德县法医部门报告了该国首例与α-甲基色胺（AMT）有关的已知死亡病例。AMT是安非他明的吲哚类似物，在20世纪60年代被研究为抗抑郁剂、兴奋剂和单胺氧化酶抑制剂。今天，AMT被认为是高中和大学年龄段男女中的一种强大的迷幻药。其受欢迎程度部分是由于众多的轶事网站讨论AMT以及其合法性和2003年4月之前通过互联网购买的可用性。在迈阿密戴德县死亡后不久，美国缉毒局紧急指定AMT为附表1管制物质。迈阿密的案件涉及一名年轻的大学生，他在死前告诉他的室友，他“服用了致幻药物”，结果“发现了宇宙的秘密”。大约12小时后，室友发现死者躺在床上没有反应。从现场回收了一个空的1克AMT小瓶，并送往毒理学实验室。通过酶倍增免疫测定技术对尿液的初步筛查为安非他明阳性，基础药物血液筛查检测到一个小峰，后来通过质谱鉴定为AMT。对于定量，AMT使用固相萃取分离，用五氟丙酸酐衍生，并使用气相色谱-质谱分析。定量分析基于AMT的m/z 276、303和466以及内标物5-甲氧基-α-甲基色胺的m/z 306、333和496。使用50 - 500 ng/mL的线性校准曲线计算样品和对照品中AMT的浓度。稀释血液、组织和胃标本，使观察到的浓度在标准曲线限度内。每次运行时提取并分析基质匹配对照品。尸检髂静脉血显示2.0 mg/L，胃内容物（尸检时采集的48 g）含有总计9.6 mg AMT，肝脏含有24.7 mg/kg，大脑含有7.8 mg/kg。另一个司法管辖区的另一个医学检查病例显示，死前血清中的浓度为1.5毫克/升。
In February 2003, the Miami-Dade County Medical Examiner Department reported the first known death in the country related to alpha-methyltryptamine (AMT). AMT is an indole analogue of amphetamine investigated in the 1960s as an antidepressant, stimulant, and monoamine oxidase inhibitor. Today, AMT is recognized as a powerful psychedelic drug among high school and college-aged men and women. Its popularity is partly due to the multitude of anecdotal websites discussing AMT as well as its legality and availability for purchase via the Internet prior to April 2003. Emergency designation of AMT as a Schedule 1 controlled substance by the Drug Enforcement Administration occurred shortly after the death in Miami-Dade County. The case in Miami involved a young college student who, prior to death, advised his roommate that he was "taking hallucinating drugs" and as a result had "discovered the secret of the universe". Approximately 12 h later, the roommate discovered the deceased lying in bed unresponsive. An empty 1-g vial of AMT was recovered from the scene and sent to the toxicology laboratory. Initial screening of urine by enzyme-multiplied immunoassay technique was positive for amphetamines, and the basic drug blood screen detected a small peak later identified by mass spectrometry as AMT. For quantitation, AMT was isolated using solid-phase extraction, derivatized with pentafluoropropionic anhydride, and analyzed using gas chromatography-mass spectrometry. Quantitative analysis was based upon m/z 276, 303, and 466 for AMT and m/z 306, 333, and 496 for the internal standard, 5-methoxy-alpha-methyltryptamine. A linear calibration curve from 50 to 500 ng/mL was used to calculate the concentration of AMT in the samples and controls. Blood, tissue, and gastric specimens were diluted to bring the observed concentration within the limits of the standard curve. Matrix matched controls were extracted and analyzed with each run. Postmortem iliac vein blood revealed 2.0 mg/L, gastric contents (48 g collected at autopsy) contained 9.6 mg total of AMT, liver contained 24.7 mg/kg, and the brain contained 7.8 mg/kg. An additional Medical Examiner case from another jurisdiction revealed 1.5 mg/L in antemortem serum.